Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
Cancer Discovery|March 15, 2014
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanibNikhil Wagle, Brian C Grabiner, Eliezer M Van Allen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 12, 2013
Small cell lung cancerGregory P Kalemkerian, Wallace Akerley, Paul Bogner, et al.
The New England Journal of Medicine|April 21, 2015
Pembrolizumab for the treatment of non-small-cell lung cancerEdward B Garon, Naiyer A Rizvi, Rina Hui, et al.
The Lancet. Oncology|September 8, 2012
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 studyD Ross Camidge, Yung-Jue Bang, Eunice L Kwak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2012
Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancerCharles M Rudin, Christine L Hann, Edward B Garon, et al.
Clinical Lung Cancer|November 5, 2025
Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 StudiesBob T Li, Leena Gandhi, Vignesh Ravichandran, et al.
Cancer Discovery|May 25, 2016
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid TumorsAmita Patnaik, Lee S Rosen, Sara M Tolaney, et al.
The New England Journal of Medicine|April 17, 2018
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung CancerLeena Gandhi, Delvys Rodríguez-Abreu, Shirish Gadgeel, et al.
Nature Communications|February 18, 2016
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpointsShohei Koyama, Esra A Akbay, Yvonne Y Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2015
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung CancerScott N Gettinger, Leora Horn, Leena Gandhi, et al.
Pageof 7